0021-972X/00/$03.00/0 Vol.85,No.9
TheJournalofClinicalEndocrinology&Metabolism PrintedinU.S.A.
Copyright©2000byTheEndocrineSociety
Effect of Calcium or 25OH Vitamin D Dietary
3
Supplementation on Bone Loss at the Hip in
Men and Women over the Age of 60*
MUNRO PEACOCK, GUANGDA LIU, MARK CAREY, RONALD MCCLINTOCK,
WALTER AMBROSIUS, SIU HUI, AND C. CONRAD JOHNSTON
DepartmentofMedicine,IndianaUniversitySchoolofMedicine,Indianapolis,Indiana46202
ABSTRACT serum25OHvitaminD was59nmol/L.Onplacebo,lossofBMDat
3
Dietarysupplementsthatpreventbonelossatthehipandthatcan totalhipwas2%andfemoralmedullaexpansionwas3%over4yr.
beappliedsafelyintheelderlyarelikelytoreducehipfractures.A Calciumreducedboneloss,secondaryhyperparathyroidism,andbone
dailydietarysupplementof750mgcalciumor15mg25OHvitamin turnover.25OHvitaminD wasintermediatebetweenplaceboand
3
D onbonelossatthehipandothersites,boneturnoverandcalcium- calcium. Fracture rates and drop-out rates were similar among
3
regulating hormones were studied over 4 yr in elderly volunteers groups, and there were no serious adverse events with either sup-
usingarandomized,double-blind,placebo-controlledtrial.Bonemin- plement.Acalciumsupplementof750mg/daypreventslossofBMD,
eraldensity(BMD)wasmeasuredbydualx-rayabsorptiometryand reducesfemoralmedullaryexpansion,secondaryhyperparathyroid-
bonestructurebyradiographs.Calciumbiochemistryandboneturn- ism,andhighboneturnover.Asupplementof15mg/day25OHvi-
over markers were measured in blood and urine. The 316 women taminD islesseffective,andbecauseitseffectsareseenonlyatlow
3
enteringthetrialhadameanageof73.7yrandthe122menof75.9 calciumintakes,suggeststhatitsbeneficialeffectistoreversecal-
yr. Baseline median calcium intake was 546 mg/day, and median ciuminsufficiency.(JClinEndocrinolMetab85:3011–3019,2000)
A
GE-RELATEDHIPfractureiscommoninbothmenand have been implicated in age-related bone loss at the hip.
women (1). The fracture is a stochastic event arising Perhaps the most common biochemical abnormalities con-
fromtheinteractionbetweenrecurrentminortraumausually sidered to be responsible for bone loss are an increase in
fromfallsanddecreasedbonestrengthatthehip(2,3).Inthe secondary hyperparathyroidism and in bone turnover
reduction of bone strength that occurs with age, both low (19, 20).
calciumintake(4,5)andlowvitaminDstores(6)havebeen A number of studies of vitamin D and calcium supple-
implicated.Dietaryintakeofcalciumdecreaseswithage(7), mentation on femoral BMD (21) and fracture (22, 23) have
andasubstantialproportionoftheelderlytakelessthanthe shown positive effects. However, because of the study de-
RecommendedDietaryAllowanceof800mg(8).Thereisalso sign, it is not clear how much of the benefit was due to
anage-relatedreductioninvitaminDstatus,amajordeter- supplementationwithvitaminDorwithcalcium.Thus,the
minantofcalciumabsorption(9).Thus,dietarysupplemen- aimsofthisstudyweretostudytheeffectonbonemassand
tation with calcium and/or with vitamin D would seem to structure at the hip and on bone turnover of maintaining
be an important health measure in hip fracture prevention. dietary calcium and serum 25-hydroxy vitamin D concen-
This is, in part, embodied in the Institute of Medicine’s trations in the upper end of the normal ranges in a sample
recent recommendations (10) that in men and women over of men and women over the age of 60.
the age of 70 yr daily Adequate Intakes would be 1200 mg
calciumand15mg(600IU)vitaminD.However,theserec-
PatientsandMethods
ommendationsarelargelybasedonstudiesinyoungerpost-
Subjects
menopausalwomen.Furthermore,therecommendationsdo
notaddressthepossibleinteractionbetweencalciumintake
Women(n5316)andmen(n5122)aged60andoverwereentered
intoarandomized,placebo-controlled,double-blindtrialontheeffect
and vitamin D status.
ofadailydietarysupplementof750mgcalciumor15mg25OHvitamin
The age-related decrease in bone strength at the hip is
D onbonemassandstructureattheupperendofthefemur.Thestudy
3
largely due to a reduction in bone mineral density (BMD) was approved by the Institutional Review Board at the Indiana Uni-
(11–15).Butchangesinbonestructure(16,17),andperhaps versitySchoolofMedicine.Minoritieswerenotexcluded,butallsubjects
boneturnover(18),alsocontribute.Anumberofmechanisms werewhiteandwererecruitedbyadvertisementsandcontactthrough
organizations for retirees from two retirement homes in Franklin, In-
diana,andfromthetownofFranklinanditsimmediateneighborhood.
ReceivedJanuary3,2000.RevisionreceivedMay3,2000.Accepted Over60%werefree-living,andallwereindependentlymobile,ableto
May19,2000. giveinformedconsentasassessedbytheShortPortableMentalStatus
Addresscorrespondenceandrequestsforreprintsto:MunroPeacock, Testandwillingtoundertakea4-yrstudy.Subjectswereexcludedifthey
M.D.,GeneralClinicalResearchCenter,UniversityHospitalandOut- hadaterminalillness;Paget’sdiseaseofbone;recurrenturinarystone
patientCenter,Room5595,550NorthUniversityBoulevard,Indianap- disease; had been treated with sodium fluoride, bisphosphonate, ste-
olis,Indiana46202. roids,ordilantin;hadrenaldiseaserequiringspecifictreatment;orwere
*SupportedbyPublicHealthServiceGrantsPHS-P01-AG05793and excludedbytheirprimaryphysician.LowBMD,previousskeletalfrac-
PHS-M01-RR-750. ture,andestrogenreplacementtherapywerenotreasonsforexclusion.
3011
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
3012 PEACOCKETAL. JCE&M†2000
Vol.85†No.9
Studydesign SerumintactPTHwasmeasuredbyadoubleantibodymethod(Nichols
Institute).TheinterassayCVis9.8%ataserumconcentrationof17.5
Thestudywasdesignedasadouble-blind,controlled-trialcomparing pg/mL,withanormalrangeof10–65pg/mL.
a calcium supplement and a supplement of 25OH vitamin D 3 with Serum 25OH vitamin D was assayed using the vitamin D-binding
appropriateplacebos.Afterbaselinestudies,subjectswererandomized proteinfromratserumand1,25(OH) vitaminDwasassayedusingthe
to1of16stratabyage(60–74and$75),sex,serum25OHvitaminD vitaminDreceptorproteinfromcalfth2
ymusafterextractionfromserum
concentration (,60 nmol/L and $60 nmol/L), and dietary calcium andpurificationonHPLC.TheinterassayCVfor25OHvitaminDis
intake(,480mg/dayand$480mg/day),whichfrompreviousstudies
10.3%ataserumconcentrationof30.3nmol/Landfor1,25(OH) vi-
wereestimatedtobeclosetothemediansforthispopulation.Assess- taminDis10.4%ataserumconcentrationof63.4pmol/L. 2
ment of dietary calcium intake was available within 24 h and serum Serumcalcium(CV52.2%at2.4mmol%),urinecalcium(CV52.2%
25OHvitaminDconcentrationwithin2weeksofthebaselinevisitand at3.9mmol%),andserumCr(CV52.0%at.4mmol%)andurineCr
didnotdelayrandomizationintothestudy.Subjectswererandomized (2.8%at8.3mmol%)weremeasuredbystandardmethodsonaRoche
into the study over a 17-month period. Subjects were seen every 6 autoanalyzer.
monthsandhadBMDmeasured,bloodandurinecollected,andques-
tionnairedatagathered.Radiographswereperformedevery12months. Fractures.Lifetimehistoryoffracturewasobtainedatthefirstvisit.Each
Ateachclinicvisit,freshsupplementandplaceboweresupplied,and subjectkeptadiaryoffractures.Ateachvisitfractureswererecorded
returned tablets and capsules were recorded. At each visit a diary of along with the type of trauma responsible, whether the fracture was
fractureswascollected,foodfrequencyquestionnairesenteredintothe confirmedbyradiographyandwhetheritrequiredsplintingorsurgery.
dietary database, and prescription and nonprescription medications TheoccurrenceofvertebralfracturesfromL4toT4wasassessedfrom
recorded. lateralthoracicandlumbarradiographstakenatthefirstandlastvisit
foreachsubject.Afracturewasdefinedasareductionoftheanterior
Medication vertebralheightof20%orgreater(25).
Diethistory.Theprevailingdietarycalciumintakewasassessedateach
Calciumsupplementwasgivenascalciumcitratemalate(Procterand
visitbytheNationalCancerInstituteHealth,Habits,andHistory(26).
Gamble,Cincinnati,OH).Tabletscontaining250mgelementalcalcium
orplaceboandcapsulescontaining5mg25OHvitaminD 3orplacebo Statisticsandanalysis
(Bone Care) were taken three times per day with meals. The 25OH
vitaminD 3contentofthecapsuleswasanalyzedevery6months,and Descriptive statistics for all variables were calculated. The three
therewasnosignificantdecreaseseenoverthe4yrofstudy.Placebos groupswerecomparedatbaselinetoevaluatethesuccessoftheran-
were of the same shape, color, and consistency as the active domization.BecausetheBMDattotalhipshowedthelowestvariance,
supplements. theprimaryoutcomeofthestudywasthechangeintotalhipBMDfrom
baselineto48monthsusinganintent-to-treatanalysis.Ifnomeasure-
Methods mentwasmadeat48months,thelastobservationwascarriedforward.
ThechangeinBMDwascomparedusingANOVA.Thedifferencesfrom
Bonemass.BMDoftherighthipwasmeasuredbydual-energyx-ray baselinewereusedastheoutcomesforthisanalysis,allowingfortreat-
absorptiometry(LunarCorp.,Madison,WI).Aftersubjectrepositioning mentandvisiteffectsandtheirinteractions.Thedatawerealsoanalyzed
themeasurementswererepeated.ThecoefficientofvariationofBMDat usingrepeatedmeasuresANOVA,whichaccountedforthecorrelation
thetotalhipwas2.13%andatfemoralneckwas2.52%(17).Wherethere overtimewithinasubject.Inthisanalysis,themissingdatawereas-
wasahistoryoffractureorreplacementbyaprosthesisontheright(n5 sumedtooccuratrandom.Toallowforthepossibilitythatthesubject’s
13),thelefthipwasmeasured.DatawereacquiredwithLunarSoftware probabilityofdropoutwasrelatedtoher/histrueBMD,therepeated-
version 1.2, and analysis was performed using software version 4.1, measuresanalysiswasextendedtoincludemodelingtheprobabilityof
whichprovidesmeasurementsattotalhip,shaft,femoralneck,Ward’s dropout (27, 28). The results of this analysis did not differ from the
triangle,andgreatertrochanter.Allscanswereanalyzedusingtheauto primary analysis described above. Interactions between calcium and
searchmode.BMDofthelumbarspineintheanteroposteriorposition vitamin D were examined by splitting the sample into high and low
andtotalbodywerealsomeasured,butnotinduplicate.Qualitycontrol calciumintakegroupsatthemediancalciumintakeandusinganalysis
wasmonitoredusinganexternalspinephantom. ofcovariancetoexaminefordifferencesintheslopesofserum25OH
vitaminDasapredictoroftotalhipBMD,serumcalcium,andserum
Bonestructure.Radiographsofthelowerpelvistoincludebothupper PTH.Asimilaranalysiswasperformedbysplittingatthemedianserum
femurs in 15-degree internal rotation were taken on standard x-ray 25OHvitaminDlevelandusingcalciumintakeasthepredictor.The
equipmentusingafocaldistanceof101.6cm.Allmeasurementswere proportions of subjects who had vertebral or non-vertebral fractures
madeonthesamehipasthatmeasuredbyDXA.Thewidthofthefemur werecomparedamonggroupsusingax2test.
andthemedullaatthemidshaftweremeasureddirectlyfromradio-
graphs by one observer using a Digimatic Caliper (Mitutoyo) as de- Results
scribedpreviously(17).Thecoefficientofvariation(CV)offemurshaft
Baselinevariables(Table1)
widthwas0.58%andfemurmedullawidthwas1.96%(17).
Baselinevariableswerecalculatedforthe282womenand
Bloodandurinebiochemistry.A24-hurineandbloodandurinetakenafter
anovernightfastwerecollectedateachvisit.Calciumandcreatinine(Cr) 111menwhohadatleastoneBMDatfemoralneck,totalhip,
weremeasuredinallurines,andcross-linkedN-telopeptideoftypeI spine, or total body measured after baseline. Compared to
collagen(NTX)inallfastingurines.Serumsfromallvisitsweremea- women,meninthisstudyweretaller,heavier,andolder,had
suredforcalcium,Cr,intactPTH,1,25(OH) vitaminD,25OHvitamin
2 a higher dietary calcium intake, BMD, width of femur me-
D,alkalinephosphatase,andosteocalcin.Inaddition,hematologyand
biochemistry for monitoring safety were measured at each visit. All dullaandcortex,serumCr,24-hurinecalcium,Crclearance
serumsamplesweresubaliqotedafterallowingthebloodtoclotand andlowerserumcalcium,PTH,1,25(OH) vitaminD,bone
2
storedat270Cuntilassayed.Allurinewassubaliqotedandstoredat
turnover markers, and fasting urine calcium/Cr ratio. The
230Cuntilassayed.
percentage of subjects above the normal range for serum
SerumosteocalcinwasmeasuredbyRIAusingarabbitpolyclonal
PTHwas8%,forserumosteocalcin11%,andforfastingurine
antiserumraisedagainstbovineosteocalcin(24).TheinterassayCVis
11.0%ataserumconcentrationof3.9ng/mLwithanormalrangeof NTX/Cr 5%.
4–19ng/100mL.
NTXinurinewasmeasuredbyanenzyme-linkedimmunoabsorbant BMDchanges(Tables2and3andFig.1)
assayusingamonoclonalantibodytohumanNTX(OstexInternational).
There were no significant sex main-effects or sex-by-
The interassay CV is 12.6% at a concentration of 124 nm/mm bone
collagenequivalentswithanormalrangeforNTX/Crof2–89nm/mm. treatmentinteractionsinanyofthevariables,and,hence,
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
CALCIUMAND25OHVITAMIND SUPPLEMENTATION 3013
3
TABLE 1. Baselinevariables,mean(SD),inanthropometry,BMD,andbiochemistryinmen(M)andwomen(W)inrelationtotreatment
groups(placebo:M537,F598;25OHvitaminD :M537,F595;calcium:M537,F589)whohadmeasurementofBMDatfemoral
3
neck,totalhip,orspineandwerestudiedatleastonevisitafterbaseline
Variable Group Placebo 25OHvitaminD Calcium
3
Height(cm) Ma 173.0(7.3) 174.7(6.0) 172.0(7.6)
W 158.0(6.6) 158.8(7.0) 158.6(6.5)
Weight(kg) Ma 80.0(8.9) 80.8(16.1) 79.7(11.1)
W 69.4(14.7) 71.0(19.9) 66.2(14.5)
Age(yr) Mb 75.4(7.6) 75.5(7.2) 76.0(7.7)
W 72.3(7.5) 74.1(8.3) 73.9(8.0)
Dietarycalcium(mg/day) Ma 629(249) 739(335) 670(325)
W 586(290) 572(267) 564(294)
TotalhipBMD(g/cm2) Ma 0.98(0.14) 0.97(0.14) 1.00(0.16)
W 0.81(0.13) 0.78(0.14) 0.79(0.13)
NeckBMD(g/cm2) Ma 0.88(0.12) 0.88(0.14) 0.90(0.18)
W 0.76(0.13) 0.75(0.13) 0.76(0.13)
L2–L4BMD(g/cm2) Ma 1.21(0.24) 1.23(0.20) 1.23(0.19)
W 1.03(0.18) 1.01(0.19) 1.00(0.19)
TotalbodyBMD(g/cm2) Ma 1.18(0.08) 1.18(0.10) 1.19(0.11)
W 1.03(0.10) 1.00(0.12) 1.02(0.11)
Femurtotalwidth(mm) Ma 38.1(2.5) 38.0(3.1) 38.0(2.7)
W 33.0(2.8) 33.7(3.0) 32.8(2.6)
Femurmedullawidth(mm) Ma 16.4(2.8) 15.9(2.7) 16.7(2.4)
Wc 14.9(2.4) 15.9(3.0) 15.2(2.5)
scalcium(mmol/L) Ma 2.25(0.10) 2.28(0.13) 2.25(0.10)
W 2.28(0.10) 2.28(0.10) 2.30(0.10)
sPTH(pg/mL) Mb 37(14) 37(14) 35(12)
W 40(19) 41(18) 44(20)
s1,25OH D(pmol/L) Ma 91(24) 94(29) 94(24)
2
W 106(31) 106(26) 101(29)
s25OHD(nmol/L) M 65.0(30) 65.0(25) 67.5(23)
W 60.0(30) 57.5(33) 62.5(25)
screatinine(mmol/L) Ma 0.12(0.02) 0.11(0.02) 0.11(0.02)
Wd 0.09(0.01) 0.09(0.02) 0.09(0.02)
Osteocalcin(ng/mL) Me 10.9(5.8) 8.7(3.7) 12.3(7.6)
W 11.8(8.7) 13.1(8.4) 11.7(7.0)
24-hurinecalcium(mmol) Mb 3.75(2.1) 3.65(2.3) 4.20(2.1)
W 3.10(1.9) 3.50(2.2) 3.28(2.0)
furineCa/Cr(mmolratio) Mb 0.25(0.11) 0.25(0.17) 0.31(0.14)
W 0.31(0.17) 0.34(0.20) 0.31(0.14)
furineNTX/Cr(nmol/mmol) Mb 33(24) 34(47) 33(24)
W 44(35) 53(40) 44(51)
Crclearance(mL/min) Ma 68(23) 72(31) 73(23)
W 61(20) 56(19) 57(18)
aP,0.01menandwomendifference.
bP,0.05menandwomendifference.
cPlaceboandvitaminDdifferences.
dPlaceboandcalciumdifference.
eCalciumandvitaminDdifference,Turkey-adjustedP,0.05.
TABLE 2. LossofBMD(g/cm2)over48monthsatthetotalhipin study(Table3)wereverysimilartothoseobservedinthe
377subjectsusinganintent-to-treatanalysis primary intent-to-treat analysis (Table 2). The placebo
grouplostBMDatthetotalhipatarateofabout0.5%per
Group n Loss P
year (P , 0.001) (Table 3 and Fig. 1). The change in BMD
Placebo 129 0.0144 0.0001
25OHVitaminD 124 0.0095 0.002 attotalhipinthecalciumgroupwassignificantlydifferent
Calcium 3 124 0.0023 0.45 from that in the placebo group (P , 0.008), but not from
Theoveralltreatmenteffectwassignificant(P50.017);Pvalues the 25OH vitamin D
3
group. The change in BMD in the
indicatesignificanceofthebonelossfromzerowithineachgroup. 25OH vitamin D group was intermediate between the
3
calciumandtheplacebogroup,butitwasnotsignificantly
menandwomenwerecombinedintheanalyses.Usingan different from either. Although the change in BMD con-
intent-to-treat analysis, the placebo group lost BMD at tinued to diverge among groups up to 4 y (Fig. 1), a
totalhip;thecalciumgroupdidnotloseBMD;andtheloss significant interaction was not detected. The changes at
of BMD in the 25OH vitamin D group was intermediate femoralneck,greatertrochanter,andWardstrianglewere
(Table2).Theoveralltreatmenteffectintheprimaryanal- similartothatatthetotalhip(datanotshown).Theeffects
ysis was significant (P 5 0.017). The results of repeated- attotalbodyweresimilartothatatthehip(Fig.1andTable
measures analysis using all available data (Fig. 1) and 3).However,atthespineallgroupsincreasedBMDduring
analysis of those subjects who completed 48 months of the study, with the change in the calcium group being
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
3014 PEACOCKETAL. JCE&M†2000
Vol.85†No.9
TABLE 3. ChangefrombaselineinBMDandmedullarywidthat
theproximalfemurinsubjectswhocompleted48monthsofstudy
Placebo 25OHVitaminD Calcium
3
n % n % n %
Men
Totalhip 22 22.91 23 21.37 19 0.33
Femoralneck 25 22.55 24 22.90 20 0.44
Spine 21 0.68 22 0.60 16 3.95
Totalbody 23 21.32 23 20.78 20 0.46
Medullarywidth 24 2.33 20 1.46 18 0.67
Women
Totalhip 50 21.71 45 22.27 51 0.12
Femoralneck 54 23.00 47 22.71 55 21.04
Spine 51 0.30 42 1.00 51 2.42
Totalbody 48 20.77 42 21.38 52 20.02
Medullarywidth 53 3.37 51 2.92 54 1.35
higher than the groups on placebo (P , 0.02) and 25OH
vitamin D (P , 0.04) (Fig. 1 and Table 3).
3
Femoralstructure(Table3andFig.2)
Theincreaseinmedullarywidthintheplacebogroupwas
significantly greater than in the calcium (P , 0.002) and
25OHvitaminD(P,0.03)groups.Therewasnosignificant
treatmenteffectontotalfemurwidth.Thus,theoveralleffect
wasadecreaseincorticalthicknessofthefemoralshaftover
4 yr in the placebo group (P , 0.007) (data not shown).
Calcium-regulatinghormones(Fig.3)
There was no difference in serum PTH between the cal-
cium and the 25OH vitamin D group, and both were sig-
3
nificantlydifferentfromplacebo(P,0.001).Changeinse-
rum 1,25 (OH) vitamin D in the calcium group was
2
significantly greater than in the placebo (P , 0.001) and
25OH vitamin D group (P , 0.002), and there was no dif-
3
ference between placebo and 25OH vitamin D group. The
3
24-hurinecalciumtoCrratioincreasedinthecalciumgroup
morethanthe25OHvitaminD group(P,0.06),whichin
3
turnincreasedmorethantheplacebo(P,0.07).Theeffects
onthefastingurinecalciumtoCrratioweresimilarbutless
marked(datanotshown).Theseresultsweresimilarwhether
groupswereexaminedwiththosewhoremainedinthestudy
for the 4 yr or who dropped out over the 4-yr period.
Biomarkers(Fig.4)
Serumosteocalcinwasdifferentbetweenthecalciumand
both the 25OH vitamin D (P , 0.001) and placebo groups
3
(P , 0.008). Urine NTX/Cr in the calcium group remained
lowerthanboththeplacebo(P,0.002)and25OHvitamin
D
3
(P , 0.02) groups. (F (cid:140)IG ). on1. thT eh ce he af nfe gc et io nfc Ba Mlc Dium at( tF h) e, t2 o5 tO alH hiv pit (a am ),i ln umD 3 ba(E r) s, pa inn ed (p bl )a ,c ae nb do
totalbody(c)withyearsonsupplement(meanand1SE).Calciumwas
CalciumintakeandvitaminDstatusinteraction(Fig.5) differentfromplaceboatthehip(P,0.008),thespine(P,0.02),and
atthetotalbody(P,0.08).25OHvitaminD andplacebodidnot
3
In subjects with calcium intakes less than the median in- differ.
take during the study of 716 mg/day, there was a positive
relationshipbetweenserum25OHvitaminDandthechange ferentforBMD(P,0.007)andPTH(P,0.001)fromthose
intotalhipBMD(P,0.06)andserumcalcium(P,0.03)and on the lower calcium intake. Similarly, analysis of the rela-
anegativerelationshipwiththechangeinserumPTH(P, tionship between calcium intake and bone loss at the hip
0.001).Insubjectswithcalciumintakesgreaterthantheme- above and below the median serum 25OH vitamin D con-
dian, these relationships were absent and significantly dif- centration showed that at the lower vitamin D status the
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
CALCIUMAND25OHVITAMIND SUPPLEMENTATION 3015
3
FIG. 2. Theeffectofcalcium(F),25OHvitaminD 3(E),andplacebo
((cid:140))onthechangeinmedullarywidthatthemidshaftofthefemur
withyearsonsupplement(meanand1SE).Theincreaseinmedullary
widthonplacebowasgreaterthanwithcalcium(P,0.002)and25OH
vitaminD (P,0.04).Therewasnodifferencebetweencalciumand
3
25OHvitaminD .
3
slopebetweencalciumandBMDatthehipwasmorepositive
than at the higher vitamin D status (P , 0.06).
Fractures(Table4)
The number of nonvertebral and vertebral fractures oc-
curring in the calcium and 25OH vitamin D supplement
3
groupsandintheplacebogroupdidnotsignificantlydiffer
(P 5 0.680).
Supplementationanddropout
The 25OH vitamin D , supplement increased the mean
3
serum 25OH vitamin D from 60.5 nmol/L to 118.8 nmol/L
at12months,whichremainedclosetothisvaluethroughout
theremainderofthestudy.Only10subjectshadserum25OH
vitaminDlessthan97.5nmol/L,andnonehadvalueshigher
than250nmol/L.Themediandietarycalciumintakeatbase-
linewas546mg/day.Inanindividualdietarycalciumintake
remainedfairlyconstant(withinpersonsd5175mg/day),
and the median intake for each group did not change
significantly over the study period. Compliance was 80%
(sd520%)forthecalciumsupplement,89%(sd516%)for
the 25OH vitamin D supplement, and 85% (sd 5 19%)
3
fortheplacebo.Thenumberofsubjectswhofailedtocom-
plete the 4-yr study was not significantly different in the FIG. 3. Theeffectofcalcium(F),25OHvitaminD 3(E),andplacebo
((cid:140))onthechangeinserumPTH(a),1,25(OH) vitaminD(b),and24-h
three groups, but was lowest in the placebo. Of the 437 2
urinecalcium/Cr(c)withyearsonsupplement(meanand1SE).PTH
subjects randomized to the study, 352 completed 1 yr, 297 changesoncalciumand25OHvitaminD weredifferentfromplacebo
3
completed2yr,271completed3yr,and236completed4yr. (P,0.001),butnotfromeachother.1,25(OH) vitaminDdecreased
2
66%ofthemenand59%ofthewomencompletedthe4yr. oncalciummorethanon25OHvitaminD 3(P,0.002)andplacebo
(P,0.001).Twenty-four-hurinecalciumoncalciumwashigherthan
The number of subjects who dropped out in the calcium
group(n571)andthe25OHvitaminDgroup(n569)were o vn ita2 m5O inH Dvit wam asin diD ff3 e( rP en, tf0 r. o0 m6) pa ln ad ceo bn op (l Pac ,eb 0o .( 0P 7), .A0. 20 40 -1 h)a un rid n2 e5 wO aH
s
higher,butnotsignificantlyso(P50.48)thanintheplacebo notcollect3
edonstudyatthefourthyearvisit.
group (n 5 61). Early withdrawal due to death (n 5 20),
fracture(n59),concurrentillness(n547),subjectrequest
(n5119),andincreasingserumCr(n56)werenotdifferent developed a kidney stone, one developed primary hyper-
inthethreegroups.Gastrointestinalsymptoms,mainlycon- parathyroidism,andoneonplacebodevelopedhypercalce-
stipation,caused12subjectstodropout,and10ofthesewere mia. All patients who dropped out were encouraged to re-
takingthecalciumsupplement.Onesubjecttakingcalcium turn for follow-up visits.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
3016 PEACOCKETAL. JCE&M†2000
Vol.85†No.9
FIG. 4. Theeffectofcalcium(F),25OHvitaminD 3(E),andplacebo((cid:140))onthechangeinosteocalcin(a)andurineNTX/Cr(b)withyearson
supplement(meanand1SE).Osteocalcinchangeoncalciumdifferedfrom25OHvitaminD 3(P,0.01)andplacebo(P,0.05).NTX/Crchange
oncalciumwaslowerthan25OHvitaminD (P,0.02)andplacebo(P,0.002).25OHvitaminD andplacebodidnotdiffer.
3 3
Safetybiochemistry above the median of 540 mg/day without increasing it be-
yond the upper end of the normal range. In general, the
The change in serum Cr concentration was not signifi-
calciumsupplementwaswelltolerated,withgastrointestinal
cantlydifferentamongplacebo,calciumand25OHvitamin
upset being the only common complaint.
D groupsoverthe4-yrstudy.Urinarycalciumincreasedin
3
the calcium supplement group (P , 0.001) and the 25OH Supplementation with oral 25OH vitamin D 3 had only a
vitamin D 3 group (P , 0.05). There was no episode of con- marginal benefit on bone loss. The 25OH vitamin D 3 sup-
sistent (i.e. remaining high on a repeated collection) hyper- plementdecreasedserumPTHtoaboutthesamedegreeas
calciuriadefinedbyafastingurineCa/Crabove0.99(mm/ thecalciumsupplement,but,incontrast,ithadlittleeffecton
mm)anda24-hurinecalciumabove7.5mmolinwomenand boneturnover.About50%ofoursubjectswereinthevitamin
8.7 mmol in men. D insufficiency range at baseline, with the median serum
25OH vitamin D being 59 nmol/L (32). Oral 25 hydroxy
Discussion vitaminD ,15mcg/day,increasedserum25OHvitaminD
3
concentrationintotheupperhalfoftheelderlynormalrange.
The beneficial effects of calcium supplementation in pre-
Themeanincreasewas58nmol/L,anincreaseexpectedwith
venting loss of BMD at the proximal femur in men and
asupplementoforalvitaminD ofabout800IU/day(33,34).
womenovertheageof60yrinthisstudywerecorroborated 3
AvitaminDsupplementgivenwithoutcalciumsupplemen-
bypositiveeffectsonBMDattotalbodyandlumbarspine.
tationhasbeenshownintheelderlytohavebeneficialeffects
Importantly,beneficialeffectsalsooccurredinthestructure
onbonemassinsomestudies.Nordinetal.(35)foundthat
ofthefemur.Theage-relatedexpansionofthefemoralmed-
15,000 IU vitamin D /week reduced the loss of metacarpal
ullarycavitywasslowed,resultinginareductionintheloss 2
cortical thickness in elderly women; in women supple-
of cortical bone. Thus, two important components of bone
mentedwith400IUvitaminD /day,Dawson-Hughesetal.
strength at the hip, BMD, and cortical thickness were pre- 3
(33)foundthatseasonalchangesinspineBMDwerelessthan
served with calcium supplementation. These beneficial ef-
womenonplacebo,whichresultedinoverallbenefittothe
fects on the proximal femur support the results of several
skeleton; and Ooms et al. (34) found that 400 IU vitamin
intervention trials in elderly women using calcium supple-
ments alone. Dawson-Hughes et al. (29) found that a 500- D 3/dayovera2-yrperiodinwomenpreventedbonelossat
mg/daycalciumsupplementreducedtherateofbonelossat the femoral neck. In the latter two studies, the vitamin D
thehipinwomenwhosedietarycalciumintakewaslessthan supplementreducedserumPTHconcentration,butasinour
400mg/day;Reidetal.(30)foundthata1000-mg/daycal- study, had no effect on bone turnover markers.
ciumsupplementhadasignificanttreatmenteffectatthehip; In subjects on placebo, BMD decreased, cortical bone
andRiggsetal.(31)foundthatacalciumsupplementof1600 thinned, secondary hyperparathyroidism progressed, and
mg/dayhadabeneficialeffectonhipBMD.Inourstudy,as highboneturnoverincreased.Therateofbonelossatthehip
inthetrialofRiggsetal.(31),thebeneficialeffectsonbone was over 0.5%/yr, a rate similar to those found in popula-
were associated with a reduction in serum PTH and in bi- tion-basedstudies(13–15).BMDattotalbodyalsodecreased,
omarkersofboneturnover,stronglysuggestingthatsubjects butatthespineitincreasedbyabout0.1%/yr.Theincrease
werecalciuminsufficientatbaseline(32).Halfofourstudy atspineinsubjectsovertheageof60isgenerallyconsidered
populationhadadailydietaryintakelessthan540mg/day, to be due to a rise in the incidence and severity of spinal
whichistypicalofthisagegroup(7).Theamountofcalcium osteoarthritisandnottoanincreaseinBMDofvertebralbone
supplement provided in this study was 750 mg/day, an (36, 37). Consistent with the observation that the skeleton
amount that increased the calcium intake of our subjects expands with age (38), femoral width increased. However,
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
CALCIUMAND25OHVITAMIND SUPPLEMENTATION 3017
3
FIG. 5. Therelationshipbetweenserum25OHvitaminDandthechangeat6monthsandat1yrinsubjectstakinglessthanthemediandaily
calciumintakeof716mgattotalhipBMD(a)(r50.13,P,0.06),serumcalcium(c)(r50.16,P,0.03),andserumPTH(e)(r520.32,P,
0.001)andinsubjectstakingmorethanthemediandailycalciumintakeof716mgattotalhipBMD(b)(r520.11,P50.11),serumcalcium
(d)(r520.02,P50.73),andserumPTH(f)(r50.05,P50.49).
themedullarycavityexpandedmorerapidlyatover0.5%/ duenotonlytosuppressionofsecondaryhyperparathyroid-
yr,whichresultedinanoveralldecreaseincorticalthickness. ism but also to the increased supply of calcium to bone.
At baseline, there was secondary hyperparathyroidism A number of trials of calcium combined with vitamin D
andincreasedturnover.Bothcalciumand25OHvitaminD supplementation on bone mass (21, 22, 39) and on fracture
3
reversedthesecondaryhyperparathyroidism.However,cal- (22, 23) have been reported. From their study design, how-
ciumhadamuchgreatereffectonboneturnoverandcalcium ever,itisdifficulttoelucidatewhetherabeneficialeffectwas
excretion,suggestingthatthebeneficialeffectsofcalciumare duetocalcium,tovitaminD,ortothecombination.Inour
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
3018 PEACOCKETAL. JCE&M†2000
Vol.85†No.9
TABLE 4. Fractures:thenumberofnonvertebralandvertebral femur.Thesupplementissafe,welltoleratedand,isappli-
fracturesthatoccurredduringthestudyinplacebo,vitaminD, cabletothegeneralpopulation.Themechanismofactionis
andcalciumgroups
probably through the reversal of a state of calcium insuffi-
ciency, resulting in an increased supply of calcium to the
Nonvertebralfractures Vertebralfractures
Group skeletonandareductioninsecondaryhyperparathyroidism
Men Women Men Women
and high bone turnover. The effect of a vitamin D supple-
Placebo 1 9 3 10
mentislessmarkedandismostbeneficialinsubjectswhoare
VitaminD 4 10 4 15
Calcium 2 9 2 5 vitamin D and calcium insufficient. A concerted effort is
requiredtoeducatetheelderlytotake1.2g/dayofcalcium
in the diet, to maintain their serum 25OHvitamin D above
study, subjects not on calcium supplements had vitamin D the vitamin D insufficiency level of 75 nmol/L with the
insufficiency(32,40)asevidencedbythenegativerelation- expectation that this will reduce the incidence of fractures,
ship between serum 25OH vitamin D and serum PTH and particularly hip fracture.
urine NTX/Cr. However, in the presence of calcium insuf-
ficiency, the concentration of serum 25OH vitamin D that Acknowledgments
separates vitamin D insufficiency from sufficiency is prob-
We are grateful to Procter and Gamble for supplying the calcium
lematicasshowninFig.5.Thesesubjectsshowedapositive
citratemalatetabletsandtheplaceboandformonitoringthestudy;to
effect of vitamin D status (serum 25OH Vitamin D concen- BoneCareforsupplyingthe25OHvitaminD capsulesandtheplacebo;
3
tration)onbonemass,indicatingthatvitaminDinsufficiency totheFranklinMasonicHomeforaccommodationtoperformthestudy;
producesastateofcalciuminsufficiency.Incontrast,ahigh and to Marcia Ryker and Cindy McClintock for the measurements
ofBMD.
vitaminDstatusincalcium-supplementedsubjectsprovided
noadditionalbenefit.Indeed,theeffectofcalciumonbone
References
losswasbluntedinsubjectswiththehighestlevelsofserum
25OH vitamin D. Whether this represents an effect of high 1. CooperC,CampionG,MeltonIIILJ.1992Hipfracturesintheelderly:a
world-wideprojection.OsteoporosisInt.2:285–289.
serum25OHvitaminDtoincreaseboneresorption(41)isnot 2. HorsmanA,MarshallDH,PeacockM.1985Astochasticmodelofage-related
clear, but it perhaps points to the danger of over-supple- bonelossandfractures.ClinOrthop.195:207–215.
3. GrissoJA,KelseyJL,StromBL,etal.andNortheastHipFractureStudy
mentation of the elderly with vitamin D if they are on an
Group.1991Riskfactorsforfallsasacauseofhipfractureinwomen.NEngl
adequate calcium intake. JMed.324:1326–1331.
There are several weaknesses in this study. Firstly, the 4. Dawson-HughesB.1991Calciumsupplementationandboneloss:areviewof
controlledclinicaltrials.AmJClinNutr.Suppl54:274S–280S.
sample of men and women recruited may not reflect the
5. NordinBEC.1997Calciumandosteoporosis.Nutrition.13:664–686.
generalelderlypopulation.However,theirratesofboneloss 6. Peacock M, Hordon L. 1989 Femoral fracture: the role of vitamin D. In:
andbiochemicalabnormalitiesaresimilartothosefoundin KleerekoperM,KraneSM,eds.Clinicaldisordersofboneandmineralme-
tabolism.NewYork:MaryAnnLiebert;265–271.
studiesoflargepopulations.Secondly,thestudycontained 7. AlaimoK,McDowellMA,BriefelRR,etal.1994Dietaryintakeofvitamins,
no minorities and the results can only be applied to white minerals,andfiberofpersonsages2monthsandoverintheUnitedStates:
ThirdNationalHealthandNutritionExaminationSurvey,Phase1,1988–91.
menandwomenovertheageof60.Thirdly,thedropoutrate
Hyattsville, MD: National Center for Health Statistics, U.S. Department of
was about 11% per year. This largely reflected the fact that HealthandHumanServices.
inclusionandexclusioncriteriaweresettoincludesubjects 8. NationalResearchCouncil1989Recommendeddietaryallowances.Wash-
ington,DC:NationalAcademyPress.
atriskofcalciumandvitaminDinsufficiencyandnotjustthe
9. BakerMR,PeacockM,NordinBEC.1980ThedeclineofvitaminDstatuswith
healthy;thatthestudywasdesignedtolast4yr;andthatthe age.AgeAging.9:249–252.
age range of the subjects was not restricted, ranging from 10. Food and Nutrition Board, Institute of Medicine. 1997 Dietary reference
intakesforcalcium,phosphorus,magnesium,vitaminD,andfluoride.Wash-
60–97.Ontheotherhand,thesubjectswerefreelivingand ington,DC:NationalAcademyPress.
not a particularly disadvantaged group such as would be 11. PearsonJ,DequekerJ,ReeveJ,etal.1995Dualx-rayabsorptiometryofthe
proximalfemur:normalEuropeanvaluesstandardizedwiththeEuropean
found with non-free living nursing home residents. Never-
spinephantom.JBoneMinRes.10:315–324.
theless,whetherthedatawereanalyzedusinganintent-to- 12. LookerAC,WahnerHW,DunnWL,etal.1995Proximalfemurbonemineral
treatanalysisorarepeatedmeasureanalysis,theresultswere levelsofU.S.adults.OsteoporosisInt.5:389–409.
13. JonesG,NguyenT,SambrookP,KellyPJ,EismanJA.1994Progressiveloss
the same.
ofboneinthefemoralneckinelderlypeople:longitudinalfindingsfromthe
Supplementationwassafewithnotroublesomehypercal- Dubboosteoporosisepidemiologystudy.BrMedJ.309:691–695.
ciuriaorhypercalcemia.Themainadverseeventwasinthe 14. BurgerH,DeLaetCE,VanDaelePL,etal.1998Riskfactorsforincreasedbone
loss in an elderly population—The Rotterdam Study. Am J Epidemiol.
calcium supplemented subjects who had more gastrointes- 147:871–879.
tinalsymptomsthanthevitaminDorplacebogroup.There 15. EnsrudKE,PalermoL,BlackDM,etal.1995Hipandcalcanealboneloss
increasewithadvancingage:longitudinalresultsfromthestudyofosteopo-
was no significant effect on fracture as expected from our
roticfractures.JBoneMinerRes.10:1778–1787.
samplesize.However,thecalcium-supplementedgrouphad 16. GluerCC,CummingsSR,PressmanA,etal.1994Predictionofhipfractures
the lowest fracture rate and the vitamin D supplement the frompelvicradiographs:thestudyofosteoporoticfractures.JBoneMinRes.
9:671–677.
highest.
17. PeacockM,LiuG,CareyM,etal.1998Bonemassandstructureatthehipin
Inconclusion,theelderlycontinuouslylosebonemassat menandwomenovertheageof60.OsteoporosisInt.8:231–239.
thehip,andasubstantialproportionofthemarecalciumand 18. MeltonIIILJ,KhoslaS,AtkinsonEJ,O’FallonWM,RiggsBL.1997Rela-
tionship of bone turnover to bone density and fractures. J Bone Min Res.
vitaminDinsufficient.Acalciumsupplementthatincreases 12:1083–1091.
thecalciumintakeclosetotheAdequateIntakeof1200mg/ 19. RiggsBL,MeltonLJI.1990Clinicalheterogeneityofinvolutionalosteoporosis:
implicationsforpreventivetherapy.JClinEndocrinolMetab.70:1229–1232.
daypreventsbonelossatthehipandatotherskeletalsites
20. DelmasPD,StennerD,WahnerHW,MannKG,RiggsBL.1983Increasein
and has beneficial effects on bone structure at the upper serum bone gamma-carboxyglutamic acid protein with aging in women.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
CALCIUMAND25OHVITAMIND SUPPLEMENTATION 3019
3
Implications for the mechanism of age-related bone loss. J Clin Invest. 1998 Long-term effects of calcium supplementation on serum parathyroid
71:1316–1321. hormonelevel,boneturnover,andbonelossinelderlywomen.JBoneMinRes.
21. ChevalleyT,RizzoliR,NydeggerV,etal.1994Effectsofcalciumsupplements 13:168–174.
onfemoralbonemineraldensityandvertebralfracturerateinvitamin-D- 32. PeacockM.1998EffectsofcalciumandvitaminDinsufficiencyontheskeleton.
repleteelderlypatients.OsteoporosisInt.4:245–252. OsteoporosisInt.8(Suppl):S45–S51.
22. Dawson-HughesB,HarrisSS,KrallEA,DallalGE.1997Effectofcalciumand 33. Dawson-HughesB,DallalGE,KrallEA,HarrisS,SokollLJ,FalconerG.1991
vitaminDsupplementationonbone,densityinmenandwomen65yearsof EffectofvitaminDsupplementationonwintertimeandoverallbonelossin
ageorolder.NEnglJMed.337:670–676. healthypostmenopausalwomen.AnnInternMed.115:505–512.
23. ChapuyMC,ArlotME,DuboeufF,etal.1992vitaminD 3andcalciumto 34. OomsME,RoosJC,BezemerPD,VanDerVijghJF,BouterLM,LipsP.1995
preventhipfracturesinelderlywomen.NEnglJMed.327:1637–1642. PreventionofbonelossbyvitaminDsupplementationinelderlywomen:a
24. Epstein S, Poser J, McClintock R, Johnston Jr CC, Bryce G, Hui S. 1984 randomizeddouble-blindtrial.JClinEndocrinolMetab.80:1052–1058.
DifferencesinserumboneGLAproteinwithageandsex.Lancet.1:307–310.
35. NordinBEC,BakerMR,HorsmanA,PeacockM.1985Aprospectivetrialof
25. MeltonIIILJ,KanSK,FryeMA,WahnerHW,O’FallonWM,RiggsBL.1989
theeffectofvitaminDsupplementationonmetacarpalbonelossinelderly
Epidemiologyofvertebralfracturesinwomen.AmJEpidemiol.129:1000–
women.AmJClinNutr.42:470–474.
1011.
36. LiuG,PeacockM,EilamO,DorullaG,BraunsteinE,JohnstonCC.1997
26. Block G, Coyle LM, Hartman AM, Scoppa SM. 1994 Revision of dietary
Effectofosteoarthritisinthelumbarspineandhiponbonemineraldensityand
analysis software for the Health Habits and History Questionnaire. Am J
diagnosis of osteoporosis in elderly men and women. Osteoporosis Int.
Epidemiol.139:1190–1196.
7:546–569.
27. Diggle PJ, Kenward MG. 1994 Informative drop-out in longitudinal data
analysis.ApplStatist.43:49–93. 37. JonesG,NguyenT,SambrookPN,KellyPJ,EismanJA.1995Alongitudinal
28. SmithDM,RobertsonWH,DigglePJ.1996Oswald:object-orientedsoftware studyoftheeffectofspinaldegenerativediseaseonbonedensityintheelderly.
for the analysis of longitudinal data in S9. Technical Report MA 96/192. JRheumatol.22:932–936.
Lancaster, UK: Department of Mathematics and Statistics, University of 38. Garn SM, Wagner B, Rohman CG, Ascoli W. 1968 Further evidence for
Lancaster. continuingboneexpansion.AmJPhysiolAnthrop.28:219–221.
29. Dawson-HughesB,DallalGE,KrallEA,SadowskiL,SahyounN,Tannen- 39. OrwollES,OviattSK,McClungMR,DeftosLJ,SextonG.1990Therateof
baumS.1990Acontrolledtrialoftheeffectofcalciumsupplementationon boneminerallossinnormalmenandtheeffectsofcalciumandcholecalciferol
bonedensityinpostmenopausalwomen.NEnglJMed.323:878–883. supplementation.AnnInternMed.112:29–34.
30. ReidIR,AmesRW,EvansMC,GambleGD,SharpeSJ.1995Long-term 40. McKennaMJ,FreaneyR.1999Secondaryhyperparathyroidismintheelderly:
effectsofcalciumsupplementationonbonelossandfracturesinpostmeno- meanstodefininghypovitaminosisD.OsteoporosisInt.8(Suppl):S3–S6.
pausalwomen:arandomizedcontrolledtrial.AmJMed.98:331–335. 41. Adams JS, Lee G. 1997 Gains in bone mineral density with resolution of
31. RiggsBL,O’FallonWM,MuhsJ,O’ConnorMK,KumarR,MeltonIIILJ. vitaminDintoxication.AnnInternMed.127:203–206.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 October 2015. at 22:51 For personal use only. No other uses without permission. . All rights reserved.
